Quetiapine as adjunctive therapy Authors: Mullen JA, et al. Title: Quetiapine adjunctive therapy for mania associated with bipolar disorder. Reference: Presented at the ICBP, Sydney, Australia 2004. [Congress poster] Purpose: To evaluate the efficacy and safety of quetiapine as adjunctive therapy to lithium or divalproex in the treatment of mania. Study design: Randomized, double-blinded, placebo-controlled trial. Follow up: 21 days. Patients: 191 patients (91 quetiapine, 100 placebo). Treatment: Quetiapine titrated to a maximum of 800 mg/day, depending on response. Results: Patients randomized to quetiapine adjunctive therapy (with lithium or divalproate) had a greater reduction in the YMRS scale, with 54% achieving a response. Discontinuation due to adverse events was similar in the quetiapine group and the placebo group.
